Nucleic acid encoding DR5 antibodies and uses thereof

• US 8,030,023 B2
• Filed: 10/10/2006
• Issued: 10/04/2011
• Est. Priority Date: 02/02/2005
• Status: Active Grant

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Ashkenazi, Avi J., Adams, Camellia W.
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US11/546,133
• Publication Number:
  US 20070031414A1
• Time in Patent Office: 1,820 Days
• Field of Search: None
• US Class Current: 435/69.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]

Abstract

The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.

Claims

1. Isolated nucleic acid encoding the heavy or light chain of an anti-DR5 antibody or a functional fragment thereof, wherein:

(a) said heavy chain comprises the variable domain sequence of 16E2 antibody heavy chain of SEQ ID NO;

11, wherein G at position 33 of CDRH1 is substituted by A, N at position 53 of CDRH2 is substituted by Q, and L at position 102 of CDRH3 is substituted by Y, and

(b) said light chain comprises the variable domain sequence of 16E2 antibody light chain of SEQ ID NO;

13, wherein Q at position 24 of CDRL1 is substituted by S, K at position 51 of CDRL2 is substituted by A, and R at position 91 of CDRL3 is substituted by A.

2. The isolated nucleic acid of claim 1 wherein said heavy chain further comprises the substitution of Q, V, E, R, K at framework residues 6, 11, 12, 13, and 105 of SEQ ID NO:

11.

3. A vector comprising the nucleic acid of claim 1 or claim 2.

4. An isolated recombinant host cell comprising the nucleic acid of claim 1 or claim 2.

5. A method of producing an anti-DR5 antibody comprising culturing the recombinant host cell of claim 4 under conditions wherein the nucleic acid is expressed.

6. The isolated nucleic acid of claim 1 wherein said anti-DR5 antibody heavy chain further comprises one or more substitutions in the framework of the full length 16E2 antibody heavy chain (SEQ ID NO:

11) variable domain.

7. The isolated nucleic acid of claim 6 wherein said anti-DR5 antibody heavy chain comprises a set of substitutions selected from the group consisting of (i) N53Q, L102Y;

(ii) M34L, N53Q, L102Y;

(iii) N53Y, L102Y;

(iv) M34L, N53Y, L102Y;

(v) G33A, N53Q, L102Y;

(vi) M34L, N53Y, L102Y;

(vii) G33A, N53Q, L102Y;

(viii) G33A, N53Y, L102Y;

(ix) T28A, N53Q, L102Y; and

(x) T28A, N53Y, L102Y in the amino acid sequence of SEQ ID NO;

11.

8. An isolated nucleic acid encoding the anti-DR5 antibody heavy chain amino acid sequence of SEQ ID NO:

18 or light chain amino acid sequence of SEQ ID NO;

20, or a fragment thereof.